Close Menu

Mayo Clinic

The Chinese company said it would use some of the funding to advance its integrated diagnostics research and development pipeline.

Researchers reclassified 86 percent of variants initially determined to be VUS, potentially changing surveillance or treatment approaches for patients.

The partners will use mass spec to look at markers in Barrett's patients who either progressed to more severe disease states or remained stable over a 10-year period.

The test uses isothermal nucleic acid amplification to return results in 20 minutes at the point of care, and demonstrated 98 percent agreement with PCR testing.

Two new studies revealed the prevalence of pathogenic variants in breast cancer-related genes, while highlighting genes that may be most informative in the clinic.

The firm said it will use the financing for ongoing development of software and learning models.

At an AMP virtual meeting workshop, a Mayo Clinic lab director offered advice on what diseases to include, how to handle VUSs, and other considerations for ECS.

The INTERCEPT study showed the potential of broader genetic testing to personalize treatment approaches for cancer patients.

Genomic and epigenomic data suggest it may be possible to target an FGFR fusion found in open chromatin in a subset of adenosquamous carcinoma of the pancreas tumors.

Using transcriptomic, metabolomic, metagenomic, and other data types, a team identified purine metabolism as a potential target for intervention.

Pages

The US Centers for Disease Control and Prevention has identified a small group of breakthrough COVID-19 cases, the Wall Street Journal reports.

The New York Times reports that the US Department of Defense is to use genetic genealogy approaches to identify the remains of unknown soldiers.

Vox and Nature discuss the importance of preparing for the next pandemic.

In Nature this week: comparison of five circulating tumor DNA assays, resequencing analysis of lettuce gives insight into its domestication, and more.